BioSpace News Archive

Business

Tevogen Bio Appoints Globally Prominent Physicist Specializing in Space Biology, COVID-19, and AI Democratization, Afshin Beheshti, to Advisory Board

Tevogen Bio Inc. announced the appointment of Afshin Beheshti, PhD, to Tevogen’s Advisory Board.

January 29, 2024
·
5 min read
Business

Novanta Inc. Schedules Earnings Release and Conference Call for Wednesday, February 28, 2024

Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its fourth quarter and full year 2023 results on Wednesday, February 28, 2024.

January 29, 2024
·
1 min read
Business

Preeclampsia Foundation Announces New 2024 Leadership of Board of Directors

The Preeclampsia Foundation welcomed a new group of officers to their 2024 Board of Directors today.

January 29, 2024
·
3 min read
BioMidwest

SenesTech Signs Poppe Enterprises for Evolve™ Distribution in Grain Management Market

SenesTech, Inc. announces a signed distribution agreement with Poppe Enterprises LLC, a distributor and pest management firm focused on the grain management market, serving Nebraska, South Dakota, North Dakota, Kansas, Wyoming, Iowa and Colorado.

January 29, 2024
·
4 min read
Pharm Country

Tyber Medical Receives FDA Clearance on Plating System Line Extension

Tyber Medical, LLC has received a U.S. Food and Drug Administration (FDA) 510(k) approval for a line extension to the existing, approved Mini-Frag System, with additional screw and plate options, and indications.

January 29, 2024
·
1 min read
BioMidwest

Insightec Announces Exablate Prime -The Next Generation of MR-guided Focused Ultrasound

Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, announced its launch of Exablate Prime, a significant enhancement to the Exablate Neuro platform.

January 29, 2024
·
4 min read
Business

Median Technologies Reports 2023 Revenue and Summarizes 2024 Strategic Outlook

Median Technologies announces its 2023 revenue, outlining both its strategic outlook and key milestones for 2024.

January 29, 2024
·
10 min read
ANGANY’s First Clinical Trial Concludes on Time and with Positive Results

ANGANY inc. announces the completion on schedule of its first clinical trial, assessing the safety and allergenicity of its therapeutic candidate against human allergy to cats.

January 29, 2024
·
2 min read